WO2002018572A3 - Membrane penetrating peptides and uses thereof - Google Patents

Membrane penetrating peptides and uses thereof Download PDF

Info

Publication number
WO2002018572A3
WO2002018572A3 PCT/US2001/026421 US0126421W WO0218572A3 WO 2002018572 A3 WO2002018572 A3 WO 2002018572A3 US 0126421 W US0126421 W US 0126421W WO 0218572 A3 WO0218572 A3 WO 0218572A3
Authority
WO
WIPO (PCT)
Prior art keywords
penetrating peptides
membrane penetrating
interest
vivo
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/026421
Other languages
French (fr)
Other versions
WO2002018572A2 (en
Inventor
Yong Guo
Clarence C Morse
Zhengbin Yao
George A Keesler Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0103110.3A external-priority patent/GB0103110D0/en
Priority to DE60133585T priority Critical patent/DE60133585T2/en
Priority to BRPI0113477 priority patent/BRPI0113477B8/en
Priority to MXPA03001622A priority patent/MXPA03001622A/en
Priority to IL15458901A priority patent/IL154589A0/en
Priority to NZ524386A priority patent/NZ524386A/en
Priority to AU8524901A priority patent/AU8524901A/en
Priority to JP2002524075A priority patent/JP4896356B2/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Priority to KR1020037002754A priority patent/KR100810927B1/en
Priority to CA2420350A priority patent/CA2420350C/en
Priority to EP01964392A priority patent/EP1360311B1/en
Publication of WO2002018572A2 publication Critical patent/WO2002018572A2/en
Priority to IL154589A priority patent/IL154589A/en
Priority to NO20030856A priority patent/NO332050B1/en
Anticipated expiration legal-status Critical
Publication of WO2002018572A3 publication Critical patent/WO2002018572A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is directed to membrane penetrating peptides useful as in vivo, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of acompound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.
PCT/US2001/026421 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof Ceased WO2002018572A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2420350A CA2420350C (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof
KR1020037002754A KR100810927B1 (en) 2000-08-25 2001-08-23 Membrane Penetrating Peptides and Uses thereof
MXPA03001622A MXPA03001622A (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof.
IL15458901A IL154589A0 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof
NZ524386A NZ524386A (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof
AU8524901A AU8524901A (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof
JP2002524075A JP4896356B2 (en) 2000-08-25 2001-08-23 Membrane-permeable peptides and uses thereof
DE60133585T DE60133585T2 (en) 2000-08-25 2001-08-23 MEMBRANE PENETRATING PEPTIDES AND ITS APPLICATIONS
EP01964392A EP1360311B1 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof
BRPI0113477 BRPI0113477B8 (en) 2000-08-25 2001-08-23 fusion protein for delivering a peptide, protein, glycoprotein or oligonucleotide into a cell
IL154589A IL154589A (en) 2000-08-25 2003-02-23 Membrane penetrating peptides and uses thereof
NO20030856A NO332050B1 (en) 2000-08-25 2003-02-24 Fusion protein for delivery of an organic molecule into a cell

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
US60/227,647 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
GB0103110.3 2001-02-07

Publications (2)

Publication Number Publication Date
WO2002018572A2 WO2002018572A2 (en) 2002-03-07
WO2002018572A3 true WO2002018572A3 (en) 2003-09-12

Family

ID=26245698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026421 Ceased WO2002018572A2 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof

Country Status (9)

Country Link
EP (1) EP1360311B1 (en)
AT (1) ATE391791T1 (en)
AU (1) AU8524901A (en)
CA (1) CA2420350C (en)
IL (1) IL154589A0 (en)
MX (1) MXPA03001622A (en)
NO (1) NO332050B1 (en)
NZ (1) NZ524386A (en)
WO (1) WO2002018572A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086927A1 (en) 1995-11-01 2003-05-08 University Of Southern California Expression of cyclin G1 in tumors
WO1998044938A1 (en) 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
FR2781674B1 (en) * 1998-07-31 2002-06-28 Inst Nat Sante Rech Med USE OF NEW CELL DEATH INDUCING AGENTS IN SYNERGY WITH INTERFERONS
EP1146869A2 (en) 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
WO2003062398A2 (en) * 2002-01-23 2003-07-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services NEW TUMOR SUPPRESSOR GENE, p28ING5
WO2003064609A2 (en) * 2002-01-29 2003-08-07 Aventis Pasteur, Ltd. Targeted immunogens
KR20030078115A (en) * 2002-03-28 2003-10-08 (주)코아바이오텍 Peptide gene carrier and method for transfecting gene into cell using the same
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
MXPA06007574A (en) * 2003-12-31 2007-04-17 Sanofi Pasteur Inc Targeted immunogens.
US8044019B2 (en) 2005-10-28 2011-10-25 Mitsubishi Tanabe Pharma Corporation Cell penetrating peptide
CN101374860A (en) * 2005-12-23 2009-02-25 技术转让合伙人公司 Synthetic peptides useful as neurotransmitter secretion inhibitors and muscle relaxation inducers
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
JP2011514160A (en) 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Methods and compositions for peptides and proteins having C-terminal elements
US8710005B2 (en) 2009-04-10 2014-04-29 Toagosei Co., Ltd. Neuronal differentiation-inducing peptide and use thereof
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
JP5858285B2 (en) * 2009-07-29 2016-02-10 東亞合成株式会社 Carrier peptide fragment and use thereof
JP5858284B2 (en) * 2009-07-29 2016-02-10 東亞合成株式会社 Carrier peptide fragments and their use
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673846B2 (en) 2009-11-02 2014-03-18 Toagosei Co. Ltd. Cell proliferation-promoting peptide and use thereof
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
WO2013180011A1 (en) 2012-05-28 2013-12-05 東亞合成株式会社 Anti-bacterial peptide and use thereof
JP6311935B2 (en) 2012-10-18 2018-04-18 東亞合成株式会社 Synthetic peptide that suppresses expression of type 2 TNF receptor and use thereof
KR101671114B1 (en) 2015-06-26 2016-10-31 충북대학교 산학협력단 Nuclear localization signal peptide derived from ULK2 and uses thereof
JP2024530931A (en) * 2021-08-06 2024-08-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Compositions and methods for the treatment and prevention of misfolded proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049325A1 (en) * 1997-04-28 1998-11-05 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
WO1999049060A1 (en) * 1998-03-25 1999-09-30 Institute Of Molecular And Cell Biology Use of growth hormone binding protein with a nuclear localization sequence (nls-ghbp)
WO1999057138A1 (en) * 1998-05-04 1999-11-11 Bristol-Myers Squibb Company Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppresssant and methods of use thereof
WO2001038547A2 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001093836A2 (en) * 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049325A1 (en) * 1997-04-28 1998-11-05 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
WO1999049060A1 (en) * 1998-03-25 1999-09-30 Institute Of Molecular And Cell Biology Use of growth hormone binding protein with a nuclear localization sequence (nls-ghbp)
WO1999057138A1 (en) * 1998-05-04 1999-11-11 Bristol-Myers Squibb Company Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppresssant and methods of use thereof
WO2001038547A2 (en) * 1999-11-24 2001-05-31 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
WO2001093836A2 (en) * 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FUTAKI SHIROH ET AL: "Arginine-rich peptides: An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 8, 17 November 2000 (2000-11-17), pages 5836 - 5840, XP002210171, ISSN: 0021-9258 *
LINDGREN M M ET AL: "Cell-penetrating peptides", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 21, no. 3, March 2000 (2000-03-01), pages 99 - 103, XP004202572, ISSN: 0165-6147 *
MITCHELL D J ET AL: "Polyarginine enters cells more efficiently than other polycationic homopolymers.", JOURNAL OF PEPTIDE RESEARCH, vol. 56, no. 5, November 2000 (2000-11-01), pages 318 - 325, XP001094094, ISSN: 1397-002X *
SCHWARZE S ET AL: "In vivo protein transduction: delivery of a biologically active protein into the mouse", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 285, no. 5433, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002140133, ISSN: 0036-8075 *
VIVES E ET AL: "A TRUNCATED HIV-1 TAT PROTEIN BASIC DOMAIN RAPIDLY TRANSLOCATES THROUGH THE PLASMA MEMBRANE AND ACCUMULATES IN THE CELL NUCLEUS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 25, 20 June 1997 (1997-06-20), pages 16010 - 16017, XP002940007, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
NZ524386A (en) 2005-10-28
CA2420350C (en) 2010-07-13
EP1360311B1 (en) 2008-04-09
NO20030856L (en) 2003-04-24
NO20030856D0 (en) 2003-02-24
CA2420350A1 (en) 2002-03-07
NO332050B1 (en) 2012-06-11
MXPA03001622A (en) 2004-09-06
WO2002018572A2 (en) 2002-03-07
AU8524901A (en) 2002-03-13
ATE391791T1 (en) 2008-04-15
EP1360311A2 (en) 2003-11-12
IL154589A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
WO2002018572A3 (en) Membrane penetrating peptides and uses thereof
BR0113477A (en) Membrane penetration peptides and their uses
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
EP2816117A3 (en) Collagen producing plants and methods of generating and using same
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2001058276A3 (en) Use of acid-stable proteases in animal feed
AU4981101A (en) Subtilisin variants
WO2004009774A3 (en) Protein conjugates with a water-soluble biocompatible, biogradable polymer
WO2005053811A3 (en) Biomolecule partition motifs and uses thereof
AU2002356861A1 (en) Fibrin membrane and methods for its preparation- application to artificial skin
IL164588A0 (en) ogenitor cells Novel methods for the invitro identification, isolation and differention of vasculogenic progenic pr
WO2001090389A3 (en) Production of silk-like proteins in plants
WO2001064738A3 (en) Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei
WO2003039442A3 (en) Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition
WO2001072264A3 (en) Pro-liposomal encapsulated preparations (iv)
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2006042661A3 (en) Oligopeptides and their use in cosmetics
WO2002022553A3 (en) Non-natural basic amino acids, their preparation and use
WO2003004517A3 (en) Peyers's patch and/or m-celle targeting ligands
WO1999064439A3 (en) Methods for increasing cationic antimicrobial peptides
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
WO1999062494A3 (en) Membrane-permeable inhibitor of dynamin-mediated endocytosis
EP1401493B8 (en) Subunit vaccines and processes for the production thereof
WO2004113511A3 (en) Cell line and uses thereof
WO2003048206A3 (en) Growth hormone agonist peptides and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2420350

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 154589

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003/01476

Country of ref document: ZA

Ref document number: 200301476

Country of ref document: ZA

Ref document number: 2002524075

Country of ref document: JP

Ref document number: 314/CHENP/2003

Country of ref document: IN

Ref document number: PA/A/2003/001622

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020037002754

Country of ref document: KR

Ref document number: 2001285249

Country of ref document: AU

Ref document number: 524386

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001964392

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037002754

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001964392

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 524386

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524386

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001285249

Country of ref document: AU